South Bow (SOBO) provides an attractive 6% dividend yield supported by distributable cash flow. Its core asset, the Keystone oil pipeline, inherited from TC Energy, faces recent pipeline incidents and ongoing operating restrictions that require caution. While Prairie Connector and Liberty Bridge projects have secured long-term customer commitments, they still face permitting, financing, and execution risks before contributing to earnings. SOBO trades at a discount compared to peers due to asset concentration and project uncertainties but offers potential for strong risk-adjusted returns if execution improves.
South Bow offers an attractive 6% dividend yield with long-term growth potential. For readers following the Energy sector, here is Pluang's market snapshot as of Oct 13, 2026 21:01 WIB: Among 62 priced Energy-sector US stocks tradable on Pluang, 47 rose and 15 fell today. Notable movers include UEC at USD 8.54 with a 1-day change of -3.34%, VG at USD 13.54 with +3.16%, and VLO at USD 449.00 with +2.98%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
